Netsteril deals with international leading brands in equipment in the field of medical device, pharmaceutical industry and life sciences.

Our principals are distinguished by their commitment to customer satisfaction, quality and innovation. We work closely with them to offer the best solution to your needs and develop long-term relationship with you.

One of our hallmarks is our wide and global view of the business. We have extensive experience and a broad knowledge of the industry rules, so that we can anticipate and offer the latest trends and advances in technology, equipment and applications.

We are assertive and transparent. We believe in honesty and integrity as basic principles to establish relationships with a common goal: achieving the best results for all parties.


Syntegon is the new brand of the former entire packaging & process division of the German group Robert Bosch, which since January 2020 has spin-off from Bosch and now operates as an independent company. The company has born as a consolidated industrial group, with a number of 64,000 machines sold in the market, 6,100 employees, 2,000 registered patents, clients in 140 countries and 30 headquarters between factories and offices.

Netsteril, S.L. is the representative in Spain only for product lines strictly related to Process Technologies, specifically:
• Sterilization: GMP pharmaceutical sterilizers such as steam autoclaves, air+steam autoclaves and superheated water autoclaves
• Bioprocess & High Purity Media systems: Water Distillers, Pure Steam Generators, Purified Water and Water For Injection Generation and Distribution Systems, Bioreactors, etc.

In addition, Netsteril, S.L. offers, through its associated company CIFA – Consultoría e Instalaciones Farmacéuticas y Alimentarias, technical services for these two product lines including installation, commissioning and qualification, with qualified personnel, both locally and internationally.
The Sterilization and Bioprocess & High Purity Media product lines have offices with factories in Ternitz (Austria) and Dresden (Germany).

Here is a brief history of each of them:

SBM – Sterilization Product Range

The Sterilization division comes from the acquired company SBM – Schoeller Bleckmann Medizintechnik – one of the worldwide leaders in pharmaceutical sterilisers. In Spain, it has references with some multinational companies manufacturing large volume parenteral solutions.
The story of SBM in this sector starts in 1972 with the taking-over of TechnoMedica, company owned by Dr. Kalasek, the inventor and patent holder of the Steam+Air Mixture Process.
SBM has more than 45 years of experience in the design, manufacturing and delivery of autoclaves for the pharmaceutical industry.

Pharmatec – Bioprocess & High Purity Media Product Range

At Syntegon, Pharmatec in Dresden (Germany) is the competence center for pharmaceutical process systems and plants to produce liquid active substances or medicinal products. In addition, Pharmatec develops and manufactures complete systems for generation, storage and distribution of high purity media for the pharmaceutical use and the biotechnology industry.


The roots of the company come from Techspray SPRL, a company founded in 2005 in Assesse (Belgium), with the initial purpose of developing spraying technologies for different markets and applications. By that starting times, GSK Vaccines in Belgium was looking for an alternative decontamination technology to the fumigation with formaldehyde. Techspray was the selected vendor and after a hard work of co-development with customer technical staff and users, they successfully validated our spraying technology for the bio-decontamination application in Pharma.

Today, under the brand name Solidfog, the company has the necessary foundations to expand internationally, offering one of the most interesting and original solutions designed for pharma industry, where GMP procedures and validation are the key factor. Their new facility is 100% focused in the research, development and supply of VH2O2 technology applied to biodecontamination. Their solutions are already used by top reference companies and sites worldwide with aseptic processing units such as GSK, Sanofi, Zoetis, Pfizer and Novartis among others.

Solidfog representada por Netsteril

STERISYS is a young and dynamic company offering an outstanding solution portfolio in two different domains: Industrial Sterilisation Equipment and Automatic Handling Systems for Prefilled Syringes.
STERISYS is market leader in Germany in the arena of EO industrial sterilisation plants with their leading technology and advanced solutions designed for the Medical Devices and Contract Sterilisation Organisations. Their holistic approach towards the EO sterilisation systems makes them different.  The production capacity of the sterilisation chamber, being the core element, is enhanced with pre-conditioning cells and degassing cells, which are installed and controlled as an integral part of the system. This approach offers greater capacity and flexibility while reducing capital expenditures and utility consumptions. Thus, STERISYS is not a mere manufacturer but a systems integrator supplying turn-key solutions.
In the industrial pharmaceutical sector, STERISYS develops, markets and supplies solutions for handling, transfer and transport nest-and-tub pre-filled syringes.

Same as other brands that we partner with, the Danish company Lytzen is the worldwide market leader in his field; the dry heat depyrogenation ovens for the pharmaceutical industry.
With more than 40 years’ experience, the key of their success has been its specialisation and their aim to meet the requirements from highly demanding customers. Lytzen has solely concentrated on heat treatment technology and its know-how about critical issues such as air flow control, attaining uniform temperature distribution and clean room classification of chambers is outstanding.
Lytzen’s long experience in construction with stainless steel for high temperature applications and their highly skilled welders allow them to manufacture unique ovens regarding lifetime and cGMP construction.


Protak Scientific Ltd is a UK-based company that is part of the Howorth Westbury Group – one of the oldest and most successful clean air technology companies in the world.

Protak Scientific was formed specifically to bring the new science of Enzyme Indicators to market. That market is predominantly pharmaceutical companies across the globe that are likely to appreciate the many benefits EI’s have over the traditional Biological Indicators.

Protak has been working closely with Public Health England (PHE) investigating tAK technology and agreeing terms to commercialise and introduce this revolutionary product to the world.

Public Health England was established on 1st April 2013, as an executive agency of the UK Department of Health, to bring together public health specialists from more than 70 organisations into a single public health service. With 5500 employees and £1 billion budget, Public Health England aims to protect and improve health and wellbeing; reduce health inequalities; provide a nationwide, integrated public health service; support people to make healthier choices; and provide expertise, information and intelligence.

Public Health England is committed to ensuring that its capabilities and discoveries are effectively developed and exploited in partnership with industry in order to benefit public health in the UK and globally. It has considerable experience of forming partnerships with industry (both major companies and SMEs) and of commercialising its Intellectual Property through licensing, forming joint ventures and creating spin out companies.

Public Health England, Porton Down (previously part of Health Protection Agency) contributes to health through the provision of services and expertise, including commissioned research programmes on microbial hazards and the maintenance of a capability to respond to future needs. It also has a proven track record in the pre-clinical development of enzymes, bio-therapeutic proteins and vaccine products.


Sterixene is a technology company specialised in UV light and pulsed light biodecontamination, assisting the sterilisation needs of their client companies with innovative fit-to-purpose approach. From the study of the idea through to the creation of the technical solution, Sterixene develops clean, compact, and efficient solutions in multiple sectors such as food industry, healthcare, and pharmaceuticals.

The company was founded in 2018 by two senior professionals with long track record in light sterilisation technologies and related industries; On one hand, Janyce Franc, the CEO and R&D director, who is a PhD in optical science, former researcher at CNRS (France’s national scientific research centre) and has 15 years of experience in innovative projects in the field of applied optics and pulsed light sterilization. On the other hand, Christophe Puisnel, the production, and quality manager, who has more than 20 years’ experience in the industry sector.

Sterixene supports their clients in three main aspects:

Microbiological studies: Upstream of your project, Sterixene carries out your feasibility studies and supports you during the validation phases. A detailed report will be sent to you on the end of the first step to assess feasibility.

Products and OEM components: Sterixene works with end-users supporting the implementation of their products onto existing systems for decontamination purposes and, also, with equipment manufacturers, to whom assist throughout all the design and integration phase of the pulsed light decontamination solution in their machines.

 Audits: Sterixene check all types of equipment with pulsed light technology in accordance with international standards. The UV-bioindicators, developed and patented by Sterixene, allow you to assess the operation and efficiency of all equipment using light as a method of decontamination: continuous UV, LED UV and obviously, the pulsed light systems.

salamanderU is a technology company formed by a multidisciplinary team of business experts in the field of life sciences, pharmaceutical engineering and computer sciences. The company aims to develop tailor-made, innovative projects, seeking the integration of technical and digital solutions. As first milestone, the company owns the first voice-electronic Batch Record software ever patented in the market.

salamanderU was founded in 2015 by Claude Dedry, Denis Decubber, Tony Donolato and Philippe Neyt.

On one hand, Claude Dedry and Denis Decubber are experts in bio-pharmaceutical processes and quality management, especially in the field of Advanced Therapies and Medicinal Products (ATMP).  They collaborate as consultants for biopharmaceutical SMEs and have successfully implement their GMP compliant business industrialization methodology, based on small productions but with very high added value. To do this, they have always bet for an innovative approach and the use of new technologies such as electronic batch records. In their multiple projects they have managed to accelerate the scale-up of production and significantly reduced operating costs.

On the other hand, Tony Donolato and Philippe Neyt are experts in pharmaceutical engineering. Their works stand out for their innovative designs and the use of new materials more versatile and resistant in the field of containment and aseptic processes. They search how to solve the difficulties of biotech companies through more efficient and flexible infrastructures, always in line with regulatory requirements.

salamanderU also controls the skills for developing and validating innovative software solutions that contribute to the reduction of operating costs. “SmartReg” is the first patented voice-controlled electronic batch record and manufacturing execution system especially designed for the ATMP market.

salamanderU is therefore the merging of a team with specific skills; it is a one stop shop  adopting a holistic and innovative approach to solve the growth and scaling-up needs of the biopharmaceutical industry, especially in the field of advanced therapies, tissue regeneration, gene therapy and cell therapy.